Innovations and strategies for the development of anticancer vaccines

Bibliography

• JENNER E: In: An Inquiry into the Causes and Effects of the Variolae Vacciniae, a Disease Discovered in some of the Western Counties of England, Particularly near Gloucester-shire, and known by the Name of the Cow Pox. Sampson & Low, London, UK (1798):213–240.
   Google Scholar
• COLEY WB: The Treatment of Inoperable Sarcoma by Bacterial Toxin (the Mixed Toxins of the Streptococcus Erysipelas and the Bacillus Prodigious). John Bale, Sons & Danielsson Ltd., London, UK (1909).
   Google Scholar
• LINEHAN DC, GOEDEGEBUURE PS, EBERLEIN, TJ: Vaccine therapy for cancer. Ann. Surg. Oncol. (1996) 3:219–228.
   PubMed Web of Science ®Google Scholar
• GROSS L: Intradermal immunization of C3I1 mice against a sarcoma that originated in animal of the same line. Cancer Res. (1943) 3:326–322.
   Google Scholar
• PREHN RT, MAIN MJ: Immunity to methylchloranthrene-induced sarcomas. J. Natl. Cancer Inst. (1957) 18:769–778.
   PubMed Web of Science ®Google Scholar
• GOEDEGEBUURE PS, BERLEIN TJ: Vaccine trials for the clinician: prospects for viral and non-viral vectors. Oncologist (1997) 2:300–308.
   PubMedGoogle Scholar
• OSANATO S: Vaccine trials for the clinician: prospects for tumor antigens. Oncologist (1997) 2:284–299.
   PubMedGoogle Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
   Google Scholar
• VAN DER BRUGGEN P, SZIKORA J-P, BOEL P et al.:Autologous cytolytic T-lymphocyte recognizes a Exp. Opin. Pharmacother. (2000) 1(4) MAGE-1 nonapeptide on melanomas expressing HLA-cw1601. Eur. J. Immunol. (1994) 21:34–40.
   Google Scholar
• GREENBERG PD: Adoptive T cell therapy of tumors:mechanisms operative in the recognition and elimina-tion of tumor cells. Adv. Immunol. (1991) 49:281–355.
   PubMed Web of Science ®Google Scholar
• YEWDELL JW, BENNINK JR: Cell biology of antigenprocessing and presentation to major histocompat-ability complex class I molecules-restricted T lympho-cytes. Adv. Immunol. (1992) 52:1–123.
   PubMed Web of Science ®Google Scholar
• ACCOLLA RS, ADORINI L, SANTORIS S, SINIGAGLIA F, GUARDIOLA J: MHC: orchestrating the immune response. Immunol. Today (1995) 16:8–11.
   PubMedGoogle Scholar
• TOPALIAN SL, SOLOMON D, ROSENBERG SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. (1989) 142:3714–3725.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, PACKARD BS, AEBERSOLD PM et al.: Useof tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl. J. Med. (1988) 319:1676–1680.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Cloningof the gene encoding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA (1994) 91:3515–3519.
   PubMed Web of Science ®Google Scholar
• HAMMARSTROM S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. (1999) 9:67–81.
   PubMed Web of Science ®Google Scholar
• ROBBINS PF, EL-GAMIL M, LI YF: A mutated beta-cateningene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. (1996) 183:1185–1192.
   PubMed Web of Science ®Google Scholar
• ABRAMS SI, KHLEIF SN, BERGMANN-LEITNER ES et al Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol (1997) 15:137–151.
   Google Scholar
• FERRONE S, MARINCOLA FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today (1995) 16:487–494.
   PubMedGoogle Scholar
• RESTIFO NP, BACIK I, IRVINE KR et al.: Antigen processing in vivo and the elicitation of primary CIT responses. J. Immunol. (1995) 154:4414–4422.
   PubMed Web of Science ®Google Scholar
• FEARON ER, PARDOLL DM, ITAYA T et al.: Interleulcin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell (1990) 60:397–403.
   PubMed Web of Science ®Google Scholar
• BLANKENSTEIN T, QIN Z, UBERLA K et al.: Tumor suppression after tumor cell-targeted tumor necrosis factor y. J. Exp. Med. (1991) 173:1047–1052.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE EM, LAZENBY AJ: Vaccination withirradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539–3543.
   PubMed Web of Science ®Google Scholar
• HARRIS JE, RYAN L, HOOVER HC JR et al.: Adjuvant activespecific irnmunotherapy for Stage II and BI colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. (2000) 18:148–157.
   Google Scholar
• ARIENTI F, BELLI F, NAPOLITANO F et al.: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Human Gene Ther. (1999) 10:2907–2916.
   PubMed Web of Science ®Google Scholar
• LI Q, NORMOLLE DP, SAYRE DM et al.: Immunological effects of BCG as an adjuvant in autologous tumor vaccines. Clin. Immunol. (2000) 94:64–72.
   PubMed Web of Science ®Google Scholar
• MITCHELL MS, KAN-MITCHELL J, KEMPF RA, HAREL W, SHAU HY, LIND S: Active specific irnmunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. (1998) 48:5883–5893.
   Google Scholar
• VERMOKEN JB, CLAESSEN AM, VAN TINTEREN H et al.: Active-specific irnmunotherapy for Stage II and Stage BI human colon cancer: a randomised trial. Lancet (1999) 353:345–350.
   Google Scholar
• BERD D, MAGUIRE HC, JR., MASTRANGELO MJ: Inductionof cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophospha-mide. Cancer Res. (1986) 46:2572–2577.
   Google Scholar
• BERD D, MAGUIRE HC, JR., MCCUE P, MASTRANGELO MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. (1990) 8:1858–1867.
   Google Scholar
• BERD D, MURPHY G, MAGUIRE HC, JR., MASTRANGELO MJ: Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. (1991) 51:2731–2734.
   PubMed Web of Science ®Google Scholar
• BERD D, MAGUIRE HC, JR., MASTRANGELO MJ: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann. NY Acad. Sci. (1993) 690:147–152.
   Google Scholar
• BERD D, MAGUIRE HC, JR., MASTRANGELO MJ, MURPHYG: Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol. Immunother (1994) 39:141–147.
   Google Scholar
• MORTON DL, FOSHAG LJ, HOON DS et al.: Prolongation of survival in metastatic melanoma after active specific irnmunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. (1992) 216:463-482. [Published erratum appears in Ann. Surg. (1993) 217:309].
   Google Scholar
• HSEUH EH, FAMATIGA E, GUPTA RK, QI K, MORTON DL: Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (Cancer Vax): correlation with survival. Ann. Surg. Oncol. (1998) 5:595–602.
   PubMed Web of Science ®Google Scholar
• WALLACK MK, SIVANANDHAM M, BALCH CM et al.: A phase BI randomized, double-blind multi-institutional trial of vaccinia melanoma oncolysates - active specific © Ashley Publications Ltd. All rights reserved. inimunotherapy for patients with Stage II melanoma. Cancer (1995) 75:34–42.
   Google Scholar
• FLEXNER S: The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J. Exp. Med. (1913) 17:553.
   PubMedGoogle Scholar
• LIVINGSTON PO, DELEO AB, JONES M, OETTGEN HF,OLD LJ: Comparison of approaches for augmenting serological responses to Meth A antigen. Pretreatment with cyclophosphamide is most effective. J. Immunol. (1983) 131:2601.
   Google Scholar
• GRANT SC, KRIS MG, HOUGHTON AN, CHAPMAN PB:Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. (1999) 5:1319–1323.
   PubMed Web of Science ®Google Scholar
• SLOVIN SF, RAGUPATHI G, ADLURI S eta/.: Carbohydratevaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA (1999) 96:5710–5715.
   Google Scholar
• YAO TJ, MEYERS M, LIVINGSTON PO et al.: Immuniza-tion of melanoma patients with BEC2-keyhold limpet hemocyanin plus BCG interderrnally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 gang,lioside antibodies. Clin. Cancer Res. (1999) 5:77–81.
   PubMed Web of Science ®Google Scholar
• FOON KA, SEN G, HUTCHINS L et al.: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialogang,lioside GD2. Clin. Cancer Res. (1998) 4:1117–1124.
   PubMed Web of Science ®Google Scholar
• ESKOLA J, KAVRTY H, TAKUIA AK et al.: randomizedprospective trials of a conjugate vaccine in the protec-tion of infants and young children against invasive Haemopbilus influenzae type b disease. N. Engl.J. Med. (1990) 323:1381–1387.
   PubMed Web of Science ®Google Scholar
• HELLING F, SHANG Y, CALVES M, OETTGEN HF, LIVING-STON PO: Increased immunogenecity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res. (1994) 54:197–203.
   PubMed Web of Science ®Google Scholar
• HELLING F, ZHANG A, SHANG A et al.: GM2-KLH conjugate vaccine: Increased immunogenecity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. (1995) 55:2783–2788.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON PO, KAELIN K, PINSKY CM, OETTGEN HF,OLD LJ: The serologic response of patients with Stage II melanoma to allogeneic melanoma cell vaccines. Cancer (1985) 56:2194–2200.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON PO, NATOLI EJ, CALVES MJ, STOCKERT E,OETTGEN HF, OLD LJ: Vaccines containing purified GM2 gang,lioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA (1987) 85:2911–2915.
   Google Scholar
• LIVINGSTON PO, RITTER G, SRIVASTAVA P et al.: Charac-terization of IgG and Ig M antibodies induced in melanoma patients by immunization with purified GM2 gang,lioside. Cancer Res. (1989) 49:7045–7050.
   PubMed Web of Science ®Google Scholar
• RESSING ME, OFFRINGA R, TOES RE et al.: Immuno-therapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immuno-technology (1996) 2:241–251.
   PubMedGoogle Scholar
• CELIS E, SETTE A, GREY HM: Epitope selection and development of peptide based vaccines to treat cancer. Sem. Cancer Biol. (1995) 6:329–336.
   PubMed Web of Science ®Google Scholar
• URBAN JL, SCHREIBER H: Tumor antigens. Ann. Rev. Immunol. (1992) 10:617–644.
   PubMed Web of Science ®Google Scholar
• BOON T, CEROTTINI JC, VAN DEN EYNDE B, VAN DER BRUGGEN P, VAN PEL A: Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol. (1994) 12:337–365.
   PubMed Web of Science ®Google Scholar
• RAMMENSEE H-G, FRIEDE T, STEVANOVIC S: MHC ligands and peptide motifs: first listing. Immunoge-netics (1995) 41:178–228.
   PubMed Web of Science ®Google Scholar
• SETTE A, VITIELLO A, REHRMAN B et al.: The relation-ship between class I binding affinity and the immuno-genecity of potential cytotoxic T cell epitopes. J Immunol. (1994) 153:5586–5592.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, SAKAGUCHI K et al.: Identifi-cation of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. (1994) 180:347–352.
   PubMed Web of Science ®Google Scholar
• MARCHAND M, WEYNANTS P, RANKIN E et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int. J. Cancer (1995) 63:883.885.
   Google Scholar
• JAEGER E, BERNHARD H, ROMERO P eta/.: Generation ofcytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer (1996) 66:162–169.
   Google Scholar
• MAYORDOMO JL, ZORINA T, SORKUS WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Med. (1995) 1:1297–1302.
   PubMed Web of Science ®Google Scholar
• YOUNG JW, INABA K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. (1996) 183:7–11.
   PubMed Web of Science ®Google Scholar
• ZHOU F, ROUSE BT, HUANG L: Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. (1992) 53:6287–6291.
   Google Scholar
• SHIRAI M, PENDLETON CD, AHLERS J, TAKESHITA T, NEWMAN M, BERZOFSKY JA: Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. (1994) 152:549–555.
   PubMed Web of Science ®Google Scholar
• MARCHAND M, WEYNANTS P, RANKING E et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int. J. Cancer (1995) 63:883–885.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients Exp. Opin. Pharmacother. (2000) 1(4) © Ashley Publications Ltd. All rights reserved. with metastatic melanoma. Nature Med. (1998) 4:321–327.
   Google Scholar
• GJERTSEN MK, BAKKA A, BREIVIK J et al.: Ex vivo raspeptide vaccination in patients with advanced pancre-atic cancer: results of a phase 1/II study. Int. J. Cancer (1996) 65:450–453.
   PubMed Web of Science ®Google Scholar
• BLACHERE NE, SRIVASTAVA PK: Heat shock protein-based cancer vaccines and related thoughts on irnmunogenecity of human tumors. Sem. Cancer Biol. (1995) 6:349–355.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA PK: Peptide-binding heat shock proteinsin the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv. Cancer Res. (1993) 62:153–177.
   PubMed Web of Science ®Google Scholar
• DAVIS HL, WHALEN RG, DEMENIEX BA: Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum. Gene Ther. (1993) 41:151–159.
   Google Scholar
• CHEN CH, JI H, SUH KW et al Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. (1999) 6:1972–1981.
   PubMed Web of Science ®Google Scholar
• FULLER DH, HAYNES JR. A qualitative progression inHIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Human Retrovit. (1994)10:1433–1441.
   PubMed Web of Science ®Google Scholar
• WANF B, UGEN EU, SRIKANTAN V et al.: Gene inocula-tion generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1993) 90:4156–4160.
   PubMed Web of Science ®Google Scholar
• CONROY RM, LOBUGLIO AF, LOECHEL F et al.: A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. (1995) 2:59–65.
   PubMed Web of Science ®Google Scholar
• WANG B, MERVA M, DANG K, UGEN KE, WILLIAMS WV,WEINER DB. Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Human Gene Ther. (1995) 6:407–418.
   Google Scholar
• NABEL G, GORDON D, BISHOP DK et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA (1996) 93:15388–15393.
   PubMed Web of Science ®Google Scholar
• IRVINE KR, RAO JB, ROSENBERG SA, RESITFO NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. (1996) 156:224–231.
   PubMed Web of Science ®Google Scholar
• ARITA I: Virological evidence for the success of thesmallpox eradication programme. Nature (1979) 279:293.
   PubMed Web of Science ®Google Scholar
• MOSS B: Vaccinia virus: a tool for research and vaccine development. Science (1991) 252:1662-1667C.
   Google Scholar
• CHAMBERLAIN RS, IRVINE KR, RESTIFO NP. The develop-ment of recombinant poxviruses for use as anticancer vaccines. In: TumorImmunotherapy. Liu S (Ed.), Academic Press, Orlando, USA (1998).
   Google Scholar
• MCCABE BJ, IRVINE KR, NISHIMURA MI: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lympho-cyte responses. Cancer Res. (1995) 55:1741–1747.
   PubMed Web of Science ®Google Scholar
• KUNDIG TM, BACHMANN MF, LEFRANCOIS L, PUDDINGTON L, HENGARTNER H, ZINKERNAGEL RM: Nonirnmunogenic tumor cells may efficiently restimu-late tumor antigen-specific cytotoxic T cells. J. Immunol. (1993) 150:4450–4456.
   PubMed Web of Science ®Google Scholar
• KANTOR J, ABRAMS S, IRVINE K, SNOY P, KAUFMAN H,SCHLOM J: Specific irnmunotherapy using a recombi-nant vaccinia virus expressing human carcinoembry-onic antigen. Ann. NY Acad. Sci. (1993) 690:370–373.
   PubMed Web of Science ®Google Scholar
• ESTIN CD, STEVENSON U, KAHN M, HELLSTROM I, HELLSTROM KE: Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97. J. Natl. Cancer Inst. (1989) 81:445–448.
   PubMedGoogle Scholar
• RONEN D, TEITZ Y, GOLDFINGER N, ROTTER V: Expres-sion of wild-type and mutant p53 proteins by recombi-nant vaccinia virus. Nucleic Acid Res. (1992) 20:3435–3441.
   PubMed Web of Science ®Google Scholar
• LATHE R, KIENY MP, GERLINGER P et al.: Tumour prevention and rejection with recombinant vaccinia. Nature (1987) 326:878–880.
   PubMed Web of Science ®Google Scholar
• BALLOUL JM, ACRES RB, GEIST M et al.: RecombinantMUC 1 vaccinia virus: a potential vector for irnmuno-therapy of breast cancer. CellMol.Biol.(1994) 40:49–59.
   Google Scholar
• HAREUVENI M, WRESCHNER D, KIENY MP: Vaccinia recombinants expressing secreted and transmem-brane forms of breast cancer-associated epithelial tumor antigen (ETA). Vaccine (1991) 9:618–626.
   PubMed Web of Science ®Google Scholar
• WANG M, BRONTE V, CHEN PW et al.: Active irnmuno-therapy of cancer with a non-replicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. (1995) 154:4685–4692.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN RS, CARROLL MW, BRONTE V et al.: Co-stimulation enhances the active irnmunotherapy effect of recombinant anticancer vaccines. Cancer Res. (1996) 56:2832–2836.
   PubMed Web of Science ®Google Scholar
• OONEY EL, COLLIER AC, GREENBERG PD et al.: Safety ofand immunological response to a recombinant virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 337:567–572.
   PubMed Web of Science ®Google Scholar
• GRAHAM BS, BELSHE RB, CLEMENTS ML et al.: Vaccina-tion of vaccinia-naive adults with human immunodefi-ciency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The Aids Vaccine Clinical Trials Network. J. Infect. Dis. (1992) 166:244–252.
   Google Scholar
• FULLER DH, HAYNES JR: A qualitative progression inHIV type 1 glycoprotein 120-specific vaccinia recombi-nant viruses: long-term inhibition of secondary vaccination. Vaccine (1993) 11:1154-1158. Exp. Opin. Pharmacother. (2000) 1(4)
   Google Scholar
• HAMILTON JM, CHEN AP, NGUYEN B et al.: Phase I studyof recombinant vaccinia virus that expresses human carcinoembryonic antigen in adult patients with adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (1994) 13:295.
   Google Scholar
• CONRY RM, KHAZAELI MB, SALEH MN et al.: Phase I trialof a recombinant vaccinia virus encoding carcinoem-bryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. (1999) 5:2330–2337.
   PubMed Web of Science ®Google Scholar
• HODGE JW, SCHLOM J, DONOHUE SJ et al.: A recombi-nant vaccinia virus expressing human prostate-specific antigen (PSA): safety and irnmunogenicity in a non-human primate. Int. J. Cancer (1995) 63:213–237.
   PubMed Web of Science ®Google Scholar
• KARR JF, KANTOR JA, HAND, PH EGGENSPERGER DL, SCHLOM J: The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Res. (1995) 55:2455–2462.
   PubMed Web of Science ®Google Scholar
• STOVER CK, DE LA CRUZ VF, FUERST TR et al.: New use of BCG for recombinant vaccines. Nature (1991) 351:456–460.
   Google Scholar
• SCHAFER R, PORTNOY DA, BRASSELL SA, PATERSON Y: Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. Immunol. (1992) 149:53–59.
   PubMed Web of Science ®Google Scholar
• PAN Z-K, IKONNOMIDIS G, LAZENBY A, PARDOLL D, PATERSON Y: A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor cell challenge and causes regression of established tumours. Nature Med. (1995) 1:471–480.
   PubMed Web of Science ®Google Scholar
• IRVINE KR, CHAMBERLAIN RS, SHULMAN EP, ROSENBERG SA, RESTIFO NP: Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J. Natl. Cancer Inst. (1997) 89:390–392.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, KAWAKAMI Y, MARINCOLA F et al.: Molecular mechanisms used by tumors to escape immune recognition: irnmunogene therapy and the cell biology of major histocompatibility complex class I. J. Immunother. (1993) 14:182–190.
   PubMed Web of Science ®Google Scholar
• LOTZE MT: Cytokine gene therapy of cancer. Cancer J. Sci. Am. (1996) 2:63–72.
   PubMedGoogle Scholar
• FYFE G, FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, LOUIE AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. (1995) 13:688–696.
   PubMed Web of Science ®Google Scholar
• MCELRATH MS: Selection of potent immunologic adjuvants for vaccine construction. Sem. Cancer Biol. (1995) 6:373–385.
   Web of Science ®Google Scholar
• IRVINE KR, CHAMBERLAIN RS, SHULMAN EP, SURMAN DR, ROSENBERG SA, RESTIFO NP: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. (1997) 89:1595–1601.
   PubMed Web of Science ®Google Scholar